Rate of non-oncology orphan medicine availability Europe 2023, by country

This statistic displays the share of non-oncology orphan drugs approved by the European Medicines Agency (EMA) between 2018 and 2021 which were available to patients in selected European countries as of January 5, 2023. According to the data, 86 percent of approved non-oncology orphan medicines were available to patients in Germany, followed by 82 percent in Italy.

Percentage of non-oncology orphan drugs approved by the EMA available to patients in Europe as of 2023, by country

Characteristic	Share of medicines available
Germany	86%
Italy	82%
France	77%
Austria	77%
Denmark	70%
England	59%
Scotland	55%
Greece	55%
Switzerland	52%
Spain**	52%
Netherlands	45%
Luxemburg	45%
Portugal	41%
Czech Republic	41%
Sweden	39%
Slovenia	34%
Romania	34%
Norway	32%
Belgium	32%
Poland	30%
Finland	27%
Ireland	25%
Hungary	23%
Cyprus*	23%
Iceland	18%
Bulgaria	16%
Slovakia	14%
Croatia*	14%
Malta*	9%
Estonia	9%
Serbia	7%
Turkey	5%
Latvia	5%
Albania*	5%
North Macedonia*	2%
Bosnia and Herzegovina*	2%
Lithuania	0%

Loading statistic...

Download

Source

Show detailed source information?

Already a member?

Sources

Use Ask Statista Research Service

Release date

April 2023

More information

Region

Europe

Survey time period

as of January 5, 2023

Supplementary notes

44 non-oncology orphan drug products were approved by the European Medicines Agency between 2018 and 2021.
In most countries availability equates to granting of access to the reimbursement list, except in DK, FI, LU. NO, SE some hospital products are not covered by the general reimbursement scheme.
* Country did not complete a full dataset and therefore availability may be unrepresentative.
** In Spain, the WAIT analysis does not identify those medicinal products being accessible earlier in conformity with Spain's Royal Decree 1015/2009 relating to Medicines in Special Situations.

Citation formats